MicroS4pMDI
Development of inhalation suspensions containing the active ingredients salmeterol xinafoate-fluticasone for inhalation under pressure
T1EDK-02667
with the co-funding of Greece and European Union
OBJECTIVE
Preparation of an inhaled long acting product of Salmeterol Xinafoate and Fluticasone Propionate for COPD treatment with improved pharmaceutical characteristics.
Chronic obstructive pulmonary disease (COPD) is one of the most common diseases worldwide, affecting the lungs and is characterized by pulmonary inflammation and irreversible airflow obstruction. The simultaneous medication of patients with a long acting bronchodilator (salmeterol) along with a corticosteroid (fluticasone), results in an ameliorated treatment of the disease. However, the everyday use of inhalation devices, provokes inconvenience especially to elderly patients. Furthermore, these active compounds are highly crystalline and consequently, they have low bioavailability while their in vitro release behavior takes place in small percentages.
MEDICAIR, a rapidly growing company with experience in producing solutions for inhalers as well as nasal sprays, and the team of Professor Bikiaris, having a large experience in the encapsulation of drugs in polymeric matrixes, are in collaboration aiming to:
- Improve the solubility, bioavailability and the in vitro release behavior of the active compounds through polymeric matrixes
- Elongate the administration of the active compounds up to 2 days
- Ameliorate the spray device, utilized for the product administration
​
Project Coordination: MEDICAIR (Schizas Dimitrios)
Principal Investigator: Prof Dimitrios Bikiaris
Duration: 04/06/2018-31/05/2021
​
Through this project, Bikiarislab had the opportunity to develop a strong collaboration with the industry combining academic research with its direct application and introduction in the market. Furthermore, during the project new researchers had the opportunity to work on the field of polymers for pharmaceutical applications.
Publications:
​
Poster presentations in international conferences:
-
G. Michailidou, S. Nanaki, D. Bikiaris Chitosan nanoparticles containing salmeterol xinafoate for respiratory use. 12th Hellenic Polymer Society International Conference (POLYCONF12), Ioannina, Greece 30 September-3 October 2018
-
G. Michailidou, N.M. Ainali, E. Xanthopoulou, D. Bikiaris Preparation and characterisation of modified chitosan with succinic anhydride and trans aconitic acid. 3rd Milan Polymer Days Congress (MIPOL2019), Milan, Italy 11-13 March 2019
-
G. Michailidou, N.M. Ainali, E. Xanthopoulou, D. Bikiaris Preparation of salmeterol xinafoate chitosan nanoparticles for chronic obstructive pulmonary disease treatment. 3rd Milan Polymer Days Congress (MIPOL2019), Milan, Italy 11-13 March 2019
-
G. Michailidou, N.M. Ainali, E. Xanthopoulou, D. Bikiaris Modified with trans aconitic acid chitosan nanoparticles containing fluticasone propionate. European Polymer Congress 2019 (EPF 2019), Hersonissos Heraklion Crete, Greece, 9-14 June 2019
-
E. Xanthopoulou, G. Michailidou, N.M. Ainali, D. Bikiaris Synthesis and characterization of modified with succinic anhydride chitosan nanoparticles containing salmeterol xinafoate. European Polymer Congress 2019 (EPF 2019), Hersonissos Heraklion Crete, Greece, 9-14 June 2019
-
G. Michailidou, N.M. Ainali, E. Xanthopoulou, D. Bikiaris Formulation of chitosan microparticles containing fluticasone propionate and salmeterol xinafoate as a method for COPD treatment. 7th International Conference on Biobased and Biodegragable Polymers (BIOPOL-2019), Stockholm, Sweden, 17-19 June 2019
-
G. Michailidou, N.M. Ainali, E. Xanthopoulou, D. Bikiaris Encapsulation of fluticasone propionate and salmeterol xinafoate in microparticles of chitosan derivative for copd treatment. The First International Conference on “Green” Polymer Materials 2020 (CGPM 2020), online, 5-25 November 2020
